The pharmaceutical industrys battle for dominance in the fastgrowing and lucrative market for treatments of hepatitis C is prompting an unprecedented legal scramble The prospect that hepatitisC drug sales could soar to  billion annually by the end of the decade is spurring attempts by drug companies to assert the patent rights theyll need to grab a piece of the pie  The
  